Name | (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydrobenzo[g]indazole-7-carboxylic acid |
---|---|
Synonyms |
unii-34zku73fu3
PF-03882845 |
Description | PF-3882845 is a remarkably high affinity selective and orally efficacious mineralocorticoid receptor (MR binding IC50=2.7 nM) antagonist for hypertension and nephropathy. PF-3882845 also binds to progesterone receptor (PR) with the binding IC50 of 310 nM[1]. |
---|---|
Related Catalog | |
Target |
IC50: 2.7 nM (mineralocorticoid receptor), 310 nM (progesterone receptor)[1] |
In Vivo | PF-3882845 reduces blood pressure, decreases urinary albumin, and protects kidney in Dahl SS rat[1]. PF-3882845 exhibits moderate oral bioavailability (F 86%) following oral administration (2 mg/kg) in male Sprague-Dawley rats[1]. PF-3882845 exhibits terminal elimination half-lives (T1/2 1.7 h) due to high plasma clearance (CL 9.8 mL/min/kg) combined with large volumes of distribution (Vdss 1.4 mL/kg respectively) following intravenous administration (2 mg/kg) in male Sprague-Dawley rats[1]. Animal Model: Male Dahl salt sensitive (SS) rats[1] Dosage: 10, 40, and 100 mg/kg Administration: Orally via gavage; twice a day; for 21 days Result: Significant blood pressure reduction was observed with 10 mg/kg. Most noticeably, rats dosed at 40 and 100 mg/kg had negligible increase in blood pressure over 21 days in the presence of high salt. |
References |
Molecular Formula | C24H22ClN3O2 |
---|---|
Molecular Weight | 419.90300 |
Exact Mass | 419.14000 |
PSA | 76.69000 |
LogP | 4.75598 |
Symbol |
GHS07 |
---|---|
Signal Word | Warning |
Hazard Statements | H315-H319-H335 |
Precautionary Statements | P261-P305 + P351 + P338 |
RIDADR | NONH for all modes of transport |